UK-based biotechnology company Autifony Therapeutics (Autifony) has completed its Phase I clinical trial of Kv3 modulator, AUT00206, to treat schizophrenia.

AUT00206 is an orally administered, active small molecule developed to selectively modulate Kv3 potassium channels.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The double blind, randomised, placebo controlled, single ascending dose and multiple ascending dose Phase I trial has  evaluated the safety, tolerability and pharmacokinetics profile of AUT00206 in more than 60 healthy volunteers.

Autifony CEO Dr Charles Large said: “We are delighted that AUT00206 is showing such a promising profile.

“It is widely recognised that there is a huge unmet need for new, more efficacious and safer treatments for schizophrenia.

See Also:

“We believe AUT00206 has the potential to be a breakthrough for patients, and we will therefore continue to seek collaborative ways to expedite development of this exciting new drug.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We believe AUT00206 has the potential to be a breakthrough for patients, and we will therefore continue to seek collaborative ways to expedite development of this exciting new drug."

It has been suggested that modulation of Kv3 channels can result in an early treatment of schizophrenia with an improved safety profile, compared to the contemporary antipsychotic treatments.

Preclinical models inform that the new approach can treat cognitive and negative symptoms, as well as positive symptoms related to the disorder.

AUT00206 was also demonstrated as safe and well tolerated, with pharmacokinetics aligned to the required drug concentrations levels, resulting in a clinical effect.

The company is planning to conduct two Phase Ib clinical trials, a ketamine challenge study and a study in schizophrenia patients to determine clinical biomarkers of efficacy.

Image: fMRI displaying normal brain control and a schizophrenic brain. Photo: courtesy of Kim J, Matthews NL, Park S.